Results 31 to 40 of about 91,870 (284)

Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease [PDF]

, 2014
Background Crohn’s disease (CD) is a chronic relapsing inflammatory condition. Many patients fail to achieve remission with medical management and require surgical interventions.
Angelberger, Angelberger, Ardizzone, Armuzzi, Armuzzi, Armuzzi, Benchimol, Bernell, Colonna, D'Haens, D'Haens, Dilger, Doherty, Ferrante, Gordon, Guyatt, Hafraoui, Hanauer, Hanauer, Herfarth, Herfarth, Higgins, Higgins, Korelitz, Manosa, Mañosa, Nos, Pitkin, Prefontaine, Regueiro, Reinisch, Reinisch, Reinisch, Reinisch, Rolfe, Rutgeerts, Savarino, Savarino, Savarino, Schünemann, Steinhart, Williams   +41 more
core   +1 more source

Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitis (focus) initiative [PDF]

, 2018
Topic: An international, expert-led consensus initiative to develop systematic, evidence-based recommendations for the treatment of noninfectious uveitis in the era of biologics.
Acharya, Nisha, Adan, Alfredo, Agrawal, Rupesh, Akkoc, Nurullah, Al Ghamdi, Saed, Al Ghamdi, Turki, Al Saati, Anood, Al-Dhibi, Hassan A., Al-Shamarani, Mohamed, Alsabaani, Nasser, Bachta, Artur, Barisani-Asenbauer, Talin, Beare, Nicholas, Belga Ottoni Porto, Fernanda, Blanco, Ricardo, Brézin, Antoine P., Carreño, Ester, Chan Sook Yee, Anita, Chandran, Vinod, Chiquet, Christophe, Cimbalas, Andrius, Cimino, Luca, Cordero-Coma, Miguel, Correspondence information about the author FMedSci, FRCOphth, Cristobal, Couto, Cuevas, Miguel, Davis, Janet L., de Boer, Joke, de la Torre, Alejandra, De Schryver, Ilse, Derzko-Dzulynsky, Larissa, Diaz-Valle, David, Dick, Andrew D., Dick, FRCOphth Andrew D., Dick†, FRCOphth Andrew D., Eugenia Duran Merino, Claudia, Eurico da Fonseca, João, Facsko, Andrea, Figueira, Luis, FMedSci,, Fonollosa, Alejandro, Fortin, Eric, FRCOphth,, FRCPCH, FRCP, FRCS, FRCOphth, FRCSEd(Ophth), FRCOphth, Gale, Richard, Galeazzi, Mauro, Garcia, Sandra, Gašperšič, Nataša, Goldstein, Debra, Guedes, Marta, Guex-Crosier, Yan, Gul, Ahmet, Hamam, Rola, Haroon, Muhammad, Hasegawa, Kenichi, Hee Chng, Hiok, Heiligenhaus, Arnd, Hisae Yamamoto, Joyce, Hooper, Claire, Hwang, De-Kuang, Hwang, Yih-Shiou, Jr., Rubens Belfort, Juanola, Xavier, Kaburaki, Toshikatsu, Kadayifcilar, Sibel, Kempen, John, Kezuka, Takeshi, Kherani, Amin, Kiak Lim, Wee, Kirsimäe, Maarja, Kotaniemi, Kaisu, Kraut, Aleksandra, Kubicka-Trząska, Agnieszka, Kuffova, Lucia, Lightman, Susan, Lim, Lyndell, MA, MD, Maria Garcia Ruiz de Morales, Jose, Massimo Accorinti, MBChB(Hons), McCluskey, Peter, McGuire, Mairide, MD,, MD,, MD,, MD,, MD†,, Mirabelli, Pierfrancesco, Miserocchi, Elisabetta, Misiuk-Hojło, Marta, Muccioli, Cristina, Murphy, Conor, Murray, Philip I., Muñoz, Santiago, Nagy, Zoltan, Namba, Kenichi, Nascimento, Heloisa, Neri, Piergiorgio, Nguyen, Quan, O'Gradaigh, Donncha, Omair, Mohammed, Otsa, Kati, Ozyazgan, Yilmaz, Pablo, Franco, PAROLI, Maria Pia, Phaik Chee, Soon, PhD, MD, PhD, MD, PhD, MD, PhD, MD, Pleyer, Uwe, Poór, Gyula, Proença, Rui, Rabinovitch, Theodore, Ramanan, Athimalaipet V., Read, Russell, Rebrov, Margarita, Recillas-Gispert, Claudia, Rosenbaum, James T., Rothova, Aniki, Salah, Sawsen, Salek, Sherveen, Schwartzman, Sergio, Seve, Pascal, Sharma, Srilakshmi, Siak, Jay, Sims, Joanne, Sohár, Nicolette, Sonoda, Koh-Hei, Steeples, Laura, Suhler, Eric, Szepessy, Zsuzsanna, Szántó, Sándor, Tappeiner, Christoph, the author FMedSci, Email, Thorne, Jennifer, Tugal Tutkun, Ilknur, Turno-Kręcicka, Anna, Van Calster, Joachim, van der Horst-Bruinsma, Irene, Vidovič Valentinčič, Nataša, Vitale, Albert, Voorduin Ramos, Stephanie, Vukojevic, Nenad, Wakefield, Denis, Willermain, François, Yalcindag, Nilufer, Yeh, Stephen, Zemaitiene, Reda, Ziouzina, Olga   +150 more
core   +1 more source

Loss of Response to Long-Term Infliximab Therapy in Children with Crohn’s Disease

Pharmaceuticals, 2013
Secondary loss of response (LoR) often precludes further use of infliximab in children with Crohn’s disease. Immunomodulators may reduce the incidence of LoR but their combination with infliximab presents safety concerns.
George Alex, Di Simpson, Anthony G. Catto-Smith, Oliver Gouldthorpe   +3 more
doaj   +1 more source

Detecting and managing small bowel Crohn’s disease – capsule endoscopy becoming a first line diagnostic method? [PDF]

, 2011
Small bowel endoscopy is crucial for diagnosing small bowel Crohn’s disease, and capsule endoscopy is complemented by balloon-assisted enteroscopy to take biopsies and by magnetic resonance imaging to visualize enteral and extra-intestinal involvement ...
Albert, Jörg Gerhard, Hausmann, Johannes   +1 more
core   +1 more source

Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis

Arthritis Research & Therapy, 2019
Introduction Biosimilar infliximab has the potential for appreciable cost savings compared to its reference biologic, but dose escalation is common and increases costs.
Jeffrey R. Curtis, Fenglong Xie, Jonathan Kay, Joel D Kallich   +3 more
doaj   +1 more source

External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease

Pharmaceutics, 2021
Infliximab is approved for treatment of various chronic inflammatory diseases including inflammatory bowel disease (IBD). However, high variability in infliximab trough levels has been associated with diverse response rates.
Christina Schräpel, Lukas Kovar, Dominik Selzer, Ute Hofmann, Florian Tran, Walter Reinisch, Matthias Schwab, Thorsten Lehr   +7 more
doaj   +1 more source

Prevalence of Systemic Lupus Erythematosus in Australia, 2010–2022: A Population‐Based Study Using Linked National Administrative Health Data

Arthritis Care &Research, EarlyView.
Objective Systemic lupus erythematosus (SLE) is a heterogenous inflammatory condition with widely varying global prevalence estimates. The frequency of SLE in the general population of Australia has been reported to be notably lower than contemporary estimates in countries such as the United States or United Kingdom, at 19 to 39 per 100,000 as opposed ...
Lucinda Roper, Rachel Black, Joanna Tieu, Winnie Chen, Matthew Parker, Catherine Hill, Natasha Nassar, Mandana Nikpour   +7 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab. [PDF]

PLoS ONE, 2017
Infliximab is an effective treatment for inflammatory bowel disease (IBD). Studies differ regarding the influence of body mass index (BMI) on the response to infliximab, with the majority of studies indicating that increased BMI may be associated with a ...
Franco Scaldaferri, Daria D'Ambrosio, Grainne Holleran, Andrea Poscia, Valentina Petito, Loris Lopetuso, Cristina Graziani, Lucrezia Laterza, Maria Teresa Pistone, Silvia Pecere, Diego Currò, Eleonora Gaetani, Alessandro Armuzzi, Alfredo Papa, Giovanni Cammarota, Antonio Gasbarrini   +15 more
doaj   +1 more source

Building a Framework for Sexual and Reproductive Health Care in the Rheumatology Context: Content and Approaches

Arthritis Care &Research, EarlyView.
People with systemic autoimmune and rheumatic diseases (SARDs) are at higher risk than the general population of experiencing adverse pregnancy and perinatal outcomes such as preeclampsia, intrauterine growth restriction, and maternal and/or fetal death.
Mehret Birru Talabi, Sonya Borrero
wiley   +1 more source